JP2012532851A5 - - Google Patents

Download PDF

Info

Publication number
JP2012532851A5
JP2012532851A5 JP2012519021A JP2012519021A JP2012532851A5 JP 2012532851 A5 JP2012532851 A5 JP 2012532851A5 JP 2012519021 A JP2012519021 A JP 2012519021A JP 2012519021 A JP2012519021 A JP 2012519021A JP 2012532851 A5 JP2012532851 A5 JP 2012532851A5
Authority
JP
Japan
Prior art keywords
antibody
seq
nos
tlr3
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012519021A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012532851A (ja
JP5800809B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/059946 external-priority patent/WO2011004028A2/en
Publication of JP2012532851A publication Critical patent/JP2012532851A/ja
Publication of JP2012532851A5 publication Critical patent/JP2012532851A5/ja
Application granted granted Critical
Publication of JP5800809B2 publication Critical patent/JP5800809B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012519021A 2009-07-10 2010-07-09 Tlr3結合剤 Expired - Fee Related JP5800809B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22454809P 2009-07-10 2009-07-10
US61/224,548 2009-07-10
PCT/EP2010/059946 WO2011004028A2 (en) 2009-07-10 2010-07-09 Tlr3 binding agents

Publications (3)

Publication Number Publication Date
JP2012532851A JP2012532851A (ja) 2012-12-20
JP2012532851A5 true JP2012532851A5 (enExample) 2013-08-15
JP5800809B2 JP5800809B2 (ja) 2015-10-28

Family

ID=42727505

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012519021A Expired - Fee Related JP5800809B2 (ja) 2009-07-10 2010-07-09 Tlr3結合剤

Country Status (10)

Country Link
US (2) US9388246B2 (enExample)
EP (1) EP2451844B1 (enExample)
JP (1) JP5800809B2 (enExample)
CN (1) CN102471382A (enExample)
AU (1) AU2010270163B2 (enExample)
CA (1) CA2766747C (enExample)
DK (1) DK2451844T3 (enExample)
ES (1) ES2543095T3 (enExample)
RU (1) RU2562865C2 (enExample)
WO (1) WO2011004028A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101683033B1 (ko) 2008-10-31 2016-12-06 얀센 바이오테크 인코포레이티드 톨-유사 수용체 3 길항제
US8460659B2 (en) 2008-10-31 2013-06-11 Janssen Biotech, Inc. Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases
CN104829714A (zh) 2008-11-03 2015-08-12 阿莱斯亚生物疗法股份有限公司 特异性地阻滞肿瘤抗原的生物活性的抗体
DK2451844T3 (en) 2009-07-10 2015-07-27 Innate Pharma Tlr3-retention agents
US20140065154A1 (en) * 2011-01-12 2014-03-06 Innate Pharma Tlr3 binding agents
CA2893376A1 (en) 2011-03-31 2012-10-04 Alethia Biotherapeutics Inc. Antibodies against kidney associated antigen 1 and antigen binding fragemnts thereof
WO2013078223A1 (en) * 2011-11-23 2013-05-30 Children's Hospital & Research Center Oakland Anti-factor h binding protein antibodies and methods of use thereof
AU2013209234B2 (en) 2012-01-09 2017-11-09 Adc Therapeutics Sa Method for treating breast cancer
CA2869316C (en) * 2012-05-09 2016-12-20 Eli Lilly And Company Anti-c-met antibodies
MX361773B (es) 2012-05-31 2018-12-17 Innate Pharma Agentes de ligación a tlr3.
ES2870004T3 (es) * 2012-08-21 2021-10-26 Janssen Pharmaceutica Nv Anticuerpos contra la risperidona y uso de los mismos
WO2015084262A2 (en) * 2013-12-03 2015-06-11 Agency For Science, Technology And Research Cytotoxic antibody
DK3186284T3 (da) 2014-08-28 2022-05-09 Bioatla Inc Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
US11111288B2 (en) 2014-08-28 2021-09-07 Bioatla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
EP4122958A1 (en) 2016-05-13 2023-01-25 BioAtla, Inc. Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
CN115427447B (zh) 2020-01-17 2025-02-18 百进生物科技公司 抗tlr7药剂和组合物以及制备和使用其的方法
US20230348571A1 (en) * 2020-04-06 2023-11-02 Vanderbilt University Cross-reactive coronavirus antibodies and uses thereof
WO2022187440A1 (en) * 2021-03-03 2022-09-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services La protien as a novel regulator of osteoclastogenesis

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5491084A (en) 1993-09-10 1996-02-13 The Trustees Of Columbia University In The City Of New York Uses of green-fluorescent protein
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AR006928A1 (es) 1996-05-01 1999-09-29 Pioneer Hi Bred Int Una molecula de adn aislada que codifica una proteina fluorescente verde como marcador rastreable para la transformacion de plantas, un metodo para laproduccion de plantas transgenicas, un vector de expresion, una planta transgenica y celulas de dichas plantas.
EP1988166A1 (en) 1997-05-07 2008-11-05 Schering Corporation Human Toll-like receptor proteins, related reagents and methods
ATE230277T1 (de) 1997-06-13 2003-01-15 Genentech Inc Stabilisierte antikörperformulierung
EP1345968A2 (en) 2000-12-28 2003-09-24 Altus Biologics Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US20050123536A1 (en) 2001-11-20 2005-06-09 Che-Leung Law Treatment of immunological disorders using anti-dc30 antibodies
CA2480059C (en) 2002-03-22 2015-11-24 Amrad Operations Pty. Ltd. Monoclonal antibody against interleukin-13 receptor alpha 1 (il-13r.alpha.1)
JP2004016021A (ja) 2002-06-12 2004-01-22 Japan Science & Technology Corp 抗体および阻害剤並びにそれを用いた形質転換方法および形質転換キット
CA2494104A1 (en) 2002-07-31 2004-04-22 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
AR051836A1 (es) * 2004-11-30 2007-02-14 Centocor Inc Antagonistas de receptor 3 simil toll metodos y usos
ES2435775T3 (es) * 2005-10-27 2013-12-23 Janssen Biotech, Inc. Moduladores de receptor tipo Toll 3, procedimientos y usos
NZ569236A (en) 2005-12-08 2012-06-29 Medarex Inc Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and their use
WO2008127347A1 (en) 2006-07-21 2008-10-23 Diadexus, Inc. Pro115 antibody compositions and methods of use
WO2008049897A1 (en) 2006-10-27 2008-05-02 Ablynx N.V. Intranasal delivery of polypeptides and proteins
WO2008140826A1 (en) 2007-05-15 2008-11-20 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
AU2009239655B2 (en) 2008-04-25 2014-05-22 Innate Pharma Improved TLR3 agonist compositions
KR101683033B1 (ko) 2008-10-31 2016-12-06 얀센 바이오테크 인코포레이티드 톨-유사 수용체 3 길항제
US8460659B2 (en) 2008-10-31 2013-06-11 Janssen Biotech, Inc. Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases
US20130090457A1 (en) 2008-10-31 2013-04-11 Janssen Biotech, Inc. Toll-Like Receptor 3 Antagonists for the Treatment of Metabolic and Cardiovascular Diseases
HUE028021T2 (en) * 2009-04-29 2016-11-28 Janssen Biotech Inc Pen-like receptor antagonists
DK2451844T3 (en) 2009-07-10 2015-07-27 Innate Pharma Tlr3-retention agents
ES2438774T3 (es) 2009-12-11 2014-01-20 Deutsches Krebsforschungszentrum Anticuerpo que se une a parvovirus H-1
US20140065154A1 (en) 2011-01-12 2014-03-06 Innate Pharma Tlr3 binding agents
MX361773B (es) 2012-05-31 2018-12-17 Innate Pharma Agentes de ligación a tlr3.

Similar Documents

Publication Publication Date Title
RU2012103212A (ru) Tlr3 связывающие агенты
HRP20191462T1 (hr) Antitijela usmjerena protiv her-3 i njihove uporabe
JP2012509881A5 (enExample)
JP2017519759A5 (enExample)
JP2022533538A5 (enExample)
US11851460B2 (en) PD1 binding agents
JP2013534809A5 (enExample)
IL290591B1 (en) Antibody drug conjugates (adc) that bind to 191p4d12 proteins
JP2022509156A5 (enExample)
JP2017535257A5 (enExample)
JP2015503909A5 (enExample)
RU2010141584A (ru) Антитело против csf-1r
JP2020514277A5 (enExample)
HRP20151019T1 (hr) PROTUTIJELA PROTIV c-MET
JP2013529904A5 (enExample)
FI3740504T3 (fi) CD70-yhdistelmähoito
RU2013125306A (ru) Связывающие протеины, специфичные по отношению к инсулин-подобным факторам роста, и их использование
JP2020522280A5 (enExample)
JP2016538318A5 (enExample)
RU2010132956A (ru) Ангиопоэтин-2-специфические связывающие агенты
JP2025183307A5 (enExample)
US20160289321A1 (en) Il-17a binding agent and uses thereof
JP2022516351A5 (enExample)
JP2024540148A5 (enExample)
JP2021512652A5 (enExample)